Lasmiditan efficacy in migraine attacks with mild vs. moderate or severe pain
| Autor: | Raghavendra Vasudeva, Mario Fernando Prieto Peres, Deborah I. Friedman, Ellen B. Dennehy, Maurice Vincent, Simin K. Baygani |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pyridines
business.industry Migraine Disorders Headache General Medicine 030204 cardiovascular system & hematology medicine.disease Lasmiditan Serotonin Receptor Agonists 03 medical and health sciences chemistry.chemical_compound Treatment Outcome 0302 clinical medicine Double-Blind Method Piperidines chemistry Migraine Anesthesia Benzamides Humans Severe pain Medicine Prospective Studies 030212 general & internal medicine business |
| Zdroj: | Current Medical Research and Opinion. 37:1031-1038 |
| ISSN: | 1473-4877 0300-7995 |
| DOI: | 10.1080/03007995.2021.1903846 |
| Popis: | To evaluate the efficacy of lasmiditan (LTN) in treating migraine attacks of mild vs. moderate or severe pain intensity.Pooled data from two single-attack, placebo-controlled studies (SAMURAI [NCT02439320] and SPARTAN [NCT02605174]), and a prospective, randomized, open-label study (GLADIATOR [NCT02565186]) were assessed. Efficacy measures included the proportion of attacks with 2-h pain freedom (PF), 2-h most bothersome symptom (MBS) freedom, and 24-h sustained pain freedom (SPF). Fisher's exact test was used to compare the proportion of PF, SPF, or MBS freedom outcomes among attacks treated at mild, moderate, or severe pain.In SAMURAI and SPARTAN, most treated attacks were of moderate (Data from two placebo-controlled, single-attack trials, and an open-label study including treatment of multiple attacks, suggested a tendency to relatively better efficacy outcomes when LTN treatment was initiated at mild vs. moderate to severe pain. Further research is needed to better understand the relationship of lasmiditan outcomes to the time of administration in the course of a migraine attack. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|